Current evidence of low-dose CT screening benefit

Area of Science:

• Oncology
• Radiology
• Public Health

Background:

• Lung cancer is the leading cause of cancer mortality globally, often diagnosed at late, incurable stages.
• Low-dose computed tomography (LDCT) screening significantly reduces mortality by enabling early diagnosis.
• Despite evidence, LDCT screening uptake remains suboptimal worldwide.

Purpose of the Study:

• To review evidence supporting LDCT screening for lung cancer.
• To highlight global implementation efforts and insights from the 1st AGILE conference.
• To discuss strategies for improving LDCT screening efficiency, equity, and impact.

Main Methods:

• Systematic review of current evidence on LDCT screening.
• Synthesis of global implementation strategies and conference insights.
• Analysis of emerging approaches like risk-based models and AI-assisted interpretation.

Main Results:

• Lung cancer screening is gaining global momentum, with national programs advancing.
• Risk-based eligibility expansion and AI integration are key strategies.
• Tailored, localized screening approaches are crucial for maximizing global impact.

Conclusions:

• LDCT screening is a cost-effective intervention to reduce lung cancer mortality.
• Optimizing screening protocols, awareness, and care pathways is essential.
• International collaboration can accelerate progress in lung cancer screening.